CIA
ALNY icon

Cape Investment Advisory’s Alnylam Pharmaceuticals ALNY Stock Holding History

Cape Investment Advisory’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.13K Buy
+27
New +$8.14K ﹤0.01% 913
2026
Q1 		– Sell
-39
Closed -$15.5K – 261
2025
Q4 		$15.5K Sell
39
-69
-64% -$30.5K ﹤0.01% 663
2025
Q3 		$49.2K Buy
108
+8
+8% +$3.26K 0.05% 225
2025
Q2 		$32.6K Buy
100
+10
+11% +$2.77K 0.01% 429
2025
Q1 		$24.3K Hold
90
– – 0.01% 444
2024
Q4 		$21.2K Hold
90
– – 0.01% 469
2024
Q3 		$24.8K Hold
90
– – 0.01% 421
2024
Q2 		$21.9K Hold
90
– – 0.01% 413
2024
Q1 		$13.5K Hold
90
– – 0.01% 490
2023
Q4 		$17.2K Sell
90
-3
-3% -$511 0.01% 563
2023
Q3 		$16.5K Hold
93
– – 0.01% 476
2023
Q2 		$17.7K Sell
93
-3
-3% -$595 0.01% 462
2023
Q1 		$19.2K Buy
+96
New +$20.2K 0.01% 428

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Cape Investment Advisory's ALNY Position: Q2 2026 in Review

Cape Investment Advisory opened a new position in Alnylam Pharmaceuticals (ALNY) in Q2 2026: 27 shares worth $8.13K. The stake represents ﹤0.01% of the portfolio and ranks #913 among its holdings. This is a return to the name: Cape Investment Advisory previously reported a position in ALNY as recently as Q4 2025.

Cape Investment Advisory first reported a position in ALNY in Q1 2023 and has held it in 13 quarters since. The position peaked at $49.2K in Q3 2025. 784 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Cape Investment Advisory held 27 shares of Alnylam Pharmaceuticals worth $8.13K as of Q2 2026.
  • Alnylam Pharmaceuticals was a new Cape Investment Advisory position in Q2 2026.
  • Alnylam Pharmaceuticals made up ﹤0.01% of Cape Investment Advisory's portfolio in Q2 2026, its #913 holding.
  • Cape Investment Advisory first reported a position in Alnylam Pharmaceuticals in Q1 2023 and has held it in 13 quarters since.
  • Cape Investment Advisory's Alnylam Pharmaceuticals position peaked at $49.2K in Q3 2025.
  • 784 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Cape Investment Advisory's 13F filing for Q2 2026, filed 23 Jul 2026.